- Depigmentation in a Patient with Chronic Myeloid Leukemia during Chemotherapy with Dasatinib
-
Choi YW, Na N, Park J
- KMID: 2451599
- Korean J Dermatol.
- 2019 Jun;57(5):292-293.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia
-
Yim E, Choi YG, Nam YJ, Lee J, Kim JA
- KMID: 2411559
- Korean J Intern Med.
- 2018 Mar;33(2):446-448.
- doi: 10.3904/kjim.2015.325
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Dasatinib (Sprycel®)-Associated Acneiform Eruption Improved by Dose Reduction due to Pleural Effusion in a Patient with Chronic Myeloid Leukemia
-
Lim JH, Woo Y, Kim M, Park HJ
- KMID: 2436860
- Korean J Dermatol.
- 2018 Aug;56(7):472-474.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib
-
Yi JH, Kim HR
- KMID: 2451060
- Blood Res.
- 2019 Mar;54(1):77-79.
- doi: 10.5045/br.2019.54.1.77
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Cytomegalovirus Colitis during Dasatinib Treatment for Patients with Hematologic Malignancy: Case Series and Literature Review
-
Choi JK, Cho SY, Choi SM, Kim GH, Lee SE, Lee S, Kim DW, Lee DG
- KMID: 2415038
- Infect Chemother.
- 2018 Jun;50(2):153-159.
- doi: 10.3947/ic.2018.50.2.153
Dasatinib, a tyrosine kinase inhibitor, is widely used for patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Although the drug has a potent immunosuppressive effect, infectious complications... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Chronic Myeloid Leukemia with Multiple Chloromas Treated Successfully with Dasatinib
-
Jang WY, Choi SM, Park MS, Ahn BC, Heo MH, Kim JY, Kwon KY, Do YR
- KMID: 2224174
- Keimyung Med J.
- 2015 Dec;34(2):120-126.
- doi: 10.0000/kmj.2015.34.2.120
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of the primitive hematopoietic stem cells. CML is characterized by the overproduction of myeloid cells, which results in marked splenomegaly and... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent Advances of Management for Chronic Myeloid Leukemia
-
Kim DW
- KMID: 2264772
- Korean J Med.
- 2012 Dec;83(6):718-723.
The clinical outcome for patients with chronic myeloid leukemia (CML) has improved radically in the past 15 years. Imatinib led to high rates of complete cytogenetic responses and improved survival... -
- CITED
-
- Close
- SHARE
-
- Close
- OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
-
Kim YK, Lee SS, Jeong SH, Ahn JS, Yang DH, Lee JJ, Shin MG, Kim HJ
- KMID: 2172154
- Chonnam Med J.
- 2014 Dec;50(3):102-111.
- doi: 10.4068/cmj.2014.50.3.102
This study explored drug transporter expression levels and their impact on clinical response to imatinib and second-generation tyrosine kinase inhibitors (TKIs) in imatinib- resistant chronic myeloid leukemia (CML). Imatinib-resistant chronic... -
- CITED
-
- Close
- SHARE
-
- Close
- Development of Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia
-
Kim H
- KMID: 2168203
- Hanyang Med Rev.
- 2012 May;32(2):103-111.
- doi: 10.7599/hmr.2012.32.2.103
Chronic myeloid leukemia (CML) is a malignant disease induced by the oncogenic signal of the BCRABL transcript resulting from the translocation between chromosome 9 and 22, t (9:22). This genetic... -
- CITED
-
- Close
- SHARE
-
- Close
- Concomitant AID Expression and BCL7A Loss Associates With Accelerated Phase Progression and Imatinib Resistance in Chronic Myeloid Leukemia
-
Yu N, Shin S, Choi JR, Kim Y, Lee KA
- KMID: 2373641
- Ann Lab Med.
- 2017 Mar;37(2):177-179.
- doi: 10.3343/alm.2017.37.2.177
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Coexisting with Clonal Evolution and BCR-ABL Mutant in CML Patients Treated with Second-generation Tyrosine Kinase Inhibitors Predict the Discrepancy of in vitro Drug Sensitivity
-
Ahn JS, Kim YK, Lee SR, Yu L, Yang DH, Cho SH, Shim HJ, Bae WK, Lee JJ, Chung IJ, Shin MG, Kim HJ
- KMID: 2165975
- Cancer Res Treat.
- 2010 Mar;42(1):37-41.
PURPOSE: Second-generation tyrosine kinase inhibitors (second TKIs) such as nilotinib and dasatinib control the activity of most ABL kinase domain mutations observed in patients with imatinib resistance. Although in vitro... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent advances in the path toward the cure for chronic myeloid leukemia
-
Kim DW
- KMID: 2251999
- Korean J Hematol.
- 2011 Sep;46(3):169-174.
- doi: 10.5045/kjh.2011.46.3.169
Through the phase 3 International Randomized Study of Interferon vs. STI571 (IRIS) trial, imatinib emerged as the standard treatment for chronic myeloid leukemia (CML) and has successfully prolonged the duration... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
-
Labots M, Gotink KJ, Dekker H, Azijli K, van der Mijn JC, Huijts CM, Piersma SR, Jiménez C, Verheul HM
- KMID: 2367555
- Exp Mol Med.
- 2016 Dec;48(12):e279.
- doi: 10.1038/emm.2016.114
Personalized cancer medicine aims to accurately predict the response of individual patients to targeted therapies, including tyrosine kinase inhibitors (TKIs). Clinical implementation of this concept requires a robust selection tool.... -
- CITED
-
- Close
- SHARE
-
- Close
- Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood
-
Koo HH
- KMID: 2284374
- Korean J Pediatr.
- 2011 Mar;54(3):106-110.
- doi: 10.3345/kjp.2011.54.3.106
In pediatric patients with acute lymphoblastic leukemia (ALL), the Philadelphia chromosome translocation is uncommon, with a frequency of less than 5%. However, it is classified as a high or very... -
- CITED
-
- Close
- SHARE
-
- Close
- Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients
-
Lee MS, Jung EA, An SB, Kim YJ, Oh DY, Song JY, Um SW, Han J, Choi YL
- KMID: 2394825
- Cancer Res Treat.
- 2017 Oct;49(4):1065-1076.
- doi: 10.4143/crt.2016.347
PURPOSE: The discoidin domain-containing receptor tyrosine kinase 2 (DDR2) is known to contain mutations in a small subset of patients with squamous cell carcinomas (SCC) of the lung. Studying the... -
- CITED
-
- Close
- SHARE
-
- Close
- Lyn Expression in Osteoblastic Osteosarcoma Tissues and Its Correlation with Clinicopathologic Factors
-
Jin MS, Khang SK, Kim MS, Choi HS, Lee JE, Kim KH, Jeon DG, Koh JS
- KMID: 2277600
- Korean J Pathol.
- 2010 Apr;44(2):125-131.
BACKGROUND: The Src family kinases (SFKs) are involved in multiple aspects of tumorigenesis, such as, proliferation, migration, and angiogenesis, and are involved in the generation and progression of many types... -
- CITED
-
- Close
- SHARE
-
- Close
- A scientific treatment approach for acute mast cell leukemia: using a strategy based on next-generation sequencing data
-
Youk J, Koh Y, Kim JW, Kim DY, Park H, Jung WJ, Ahn KS, Yun H, Park I, Sun CH, Lee S, Yoon SS
- KMID: 2172740
- Blood Res.
- 2016 Mar;51(1):17-22.
- doi: 10.5045/br.2016.51.1.17
BACKGROUND: Mast cell leukemia (MCL) is the most aggressive form of systemic mastocytosis disorders. Owing to its rarity, neither pathogenesis nor standard treatment is established for this orphan disease. Hence,... -
- CITED
-
- Close
- SHARE
-
- Close
- MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia
-
Lardo M, Castro M, Moiraghi B, Rojas F, Borda N, Rey JA, Lazarowski A
- KMID: 2172758
- Blood Res.
- 2015 Sep;50(3):154-159.
- doi: 10.5045/br.2015.50.3.154
BACKGROUND: Tyrosine kinase inhibitors (TKIs) are the recommended treatment for patients with chronic myeloid leukemia (CML). The MDR1/ABCB1 gene plays a role in resistance to a wide spectrum of drugs,... -
- CITED
-
- Close
- SHARE
-
- Close
- Korean Guidelines for Treating Chronic Myelogenous Leukemia - The Korean Society of Hematology Chronic Myelogenous Leukemia Working Party
-
Kim DY, Lee JO, Kim KH, Kim BS, Kim SH, Kim YK, Kim HJ, Kim I, Park S, Park JS, Chung JS, Cheong JW, Jung CW, Jo DY, Sohn SK, Chronic Myelogenous Leukemia Working Party, the Korean Society of Hematology
- KMID: 2269125
- Korean J Med.
- 2015 Apr;88(4):406-419.
- doi: 10.3904/kjm.2015.88.4.406
BACKGROUND/AIMS: The first edition of the Korean treatment guidelines for chronic myelogenous leukemia (CML) was published in 2006. We intend to update those guidelines to include the use of next-generation... -
- CITED
-
- Close
- SHARE
-
- Close
- Erythroleukemic Blast Crisis of Chronic Myeloid Leukemia
-
Chung HJ, Chi HS, Seo EJ, Jang S, Park CJ, Lee KH
- KMID: 2238832
- Korean J Lab Med.
- 2006 Aug;26(4):255-262.
- doi: 10.3343/kjlm.2006.26.4.255
Erythroleukemic blast crisis of chronic myeloid leukemia (CML) is very rare. We report two cases of erythroleukemic blast crisis of CML resistant to imatinib treatment. Both patients made a rapid... -
- CITED
-
- Close
- SHARE
-
- Close
